• No results found

Pathophysiology and management of coagulation disorders in critical care medicine - Contents

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "Pathophysiology and management of coagulation disorders in critical care medicine - Contents"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 3 pagina )

Hele tekst

(1)

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)

UvA-DARE (Digital Academic Repository)

Pathophysiology and management of coagulation disorders in critical care

medicine

de Jonge, E.

Publication date 2000

Link to publication

Citation for published version (APA):

de Jonge, E. (2000). Pathophysiology and management of coagulation disorders in critical care medicine.

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

(2)

Contents s

Chapterr 1

Generall introduction and outline of the thesis 9

Chapterr 2

Currentt drug treatment strategies for disseminated intravascular coagulation n

DrugsDrugs 1998;55:767-777 15

Chapterr 3

Coagulationn abnormalities in sepsis: relation with inflammatory responses

CurrentCurrent Opinion in Critical Care, October 2000, in press 33 Chapterr 4

Tissuee factor pathway inhibitor (TFPI) dose-dependently inhibits coagulationn activation without influencing the fibrinolytic and cytokine responsee during human endotoxemia

BloodBlood 2000;95:1124-1129 49

Chapterr 5

Tissuee factor pathway inhibitor (TFPI) does not influence inflammatory pathwayss during human endotoxemia

submittedsubmitted for publication 69

Chapterr 6

Activationn of coagulation by administration of recombinant factor Vila

(3)

Chapterr 7

Thee in vivo kinetics of tissue factor mRNA expression during human endotoxemia:: relationship with activation of coagulation

BloodBlood 2000;96:554-559 95

Chapterr 8

Effectss of different plasma substitutes on blood coagulation. A comparative review w

acceptedaccepted for publication in Critical Care Medicine 115 Chapterr 9

Impairedd haemostasis by intravenous administration of a gelatin-based plasmaa expander in human subjects

ThrombosisThrombosis and Haemostasis 1998;79:286-290 131 Chapterr 10

Decreasedd circulating levels of von Willebrand factor after intravenous administrationn of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) inn healthy human subjects

submittedsubmitted for publication 143

Chapterr 11

Pharmacologicall strategies to decrease excessive blood loss in cardiacc surgery: a meta-analysis of clinically relevant end points

LancetLancet 1999;354:1940-1947 157

Summaryy 181 Samenvattingg 185 Dankwoordd 191

Referenties

Download het nu ( PDF - 3 pagina - 176.76 KB )

GERELATEERDE DOCUMENTEN

A combinatorial approach towards pharmaceutically relevant cyclic peptides - List of abbreviations

Asn asparagine Asp aspartic acid Cys cysteine Gln glutamine Glu glutamic acid Gly glycine His histidine Ile isoleucine Leu leucine Lys lysine Met methionine

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 1: General introduction

To date not only a vast number of peptides have been identified from natural sources, but also their synthesis now has reached the stage that peptides up to 50 residues may be

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 2: Improved auxiliary for the synthesis of medium-sized bis(lactams)

Removal of the N-Boc protective group by treatment with TFA and subsequent neutralization to induce the O →N acyl transfer reaction resulted in the formation of the desired lactam

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 3: Backbone amide linker strategy for the synthesis of 1,4-triazole containing cyclic tetra- and pentapeptides

Reaction mixture was diluted with EtOAc (30 mL) and the organic layer was washed with water, saturated aqueous sodium bicarbonate solution and a 1 M solution of

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 4: Synthesis of 1,5-connected triazole-containing cyclic pseudotetrapeptides

After stirring overnight at room temperature the mixture was diluted with CHCl 3 (90 mL) and washed with water (100 mL), an aqueous solution of saturated.. sodium bicarbonate

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 5: Combined ugi-4CR and azide-alkyne cycloaddition reaction for the fast assembly of small and diverse cyclic peptides

As the combination of the Ugi-4CR and the copper-catalyzed azide-alkyne cycloaddition reaction had efficiently provided access to small cyclic pseudopeptides, this method was

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Chapter 6: Retrospection and outlook

The use of the linker developed for the combinatorial synthesis of 1,4-connected triazole-containing cyclic peptides described in Chapter 3, may also be used for these

A combinatorial approach towards pharmaceutically relevant cyclic peptides - Summary

This thesis deals with several combinatorial approaches for the synthesis of cyclic peptides 1 and pseudopeptides 2-3, ranging from the smallest homodiketopiperazines to